Lausanne, May 29, 2024 – Novigenix, a leader in AI-driven healthcare solutions, has been awarded the prestigious recognition of ‘Best 2024 Technology Innovation’ in oncology by the MATWIN Board, the premier European convention dedicated to innovation in cancer treatment. This recognition highlights Novigenix’s groundbreaking contributions to personalized cancer care and its commitment to advancing oncology through cutting-edge technology.
Brian Hashemi, CEO of Novigenix, said, “This is a strong acknowledgment of our team’s commitment to advancing oncology solutions using AI and RNA analysis. We are deeply grateful to the MATWIN Board members for this award and look forward to continuing our efforts to make significant strides in immuno-oncology R&D.“
Novigenix’s recognition by the MATWIN International Board underscores its pivotal role in transforming cancer care through technological innovation and AI-driven solutions. Novigenix is leveraging advanced AI and RNA analysis of liquid biopsy to provide precise insights into patient immune responses to cancer treatments. Insights into the dynamic nature of the patient’s immune response pave the way for groundbreaking therapeutic discoveries by incorporating perspectives of patient immunity and host reactions, a relatively new concept in the field.
MATWIN is a French national open-innovation platform fully owned by Unicancer that focuses exclusively on accelerating translational research in oncology. The MATWIN International Board brings together around twenty key decision-makers from global oncology R&D laboratories and academic opinion leaders from major European cancer research centers. MATWIN Board is composed major international groups involved in oncology such as Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Exact Sciences, GlaxoSmithKline, Insitro MSD, Pfizer, Pierre Fabre, Roche, Sanofi and Takeda.
Jean-Pierre Bizzari, member of the MATWIN International Board and expert in clinical development (Aventis, Sanofi, Celgene), commented, “Novigenix’s immune pathway analysis is exactly the technology that the field needs. It can truly be disruptive by accelerating our understanding of patient heterogeneity, drug development, and potentially novel drug targets.”
Miro Venturi, Board Member of Novigenix emphasized the value of transcriptomic insights in oncology, “Harnessing the power of transcriptomics allows us to gain a deeper understanding of tumor-host interactions and patient-specific responses. This is invaluable for developing precision oncology therapies and improving patient outcomes.”
_______________
About Novigenix
Novigenix pioneers AI-driven healthcare solutions, analyzing RNA data to personalize cancer treatments and improve patient outcomes. Leveraging molecular technologies and AI, Novigenix maps systemic immune responses, facilitating tailored therapeutic advancements based on individual immune response profiles.
For over a decade, Novigenix has demonstrated leadership in bringing precision immunology to the market, integrating multi-omics data with AI through its proprietary LITOSeek™ platform. This innovative approach offers insights into patient immune responses, driving precision therapy developments.
About MATWIN
MATWIN (Maturation & Accelerating Translation With Industry), a subsidiary of Unicancer, is the only French open-innovation platform specifically dedicated to oncology. For fifteen years, the platform has offered various actions (accelerator program, entrepreneurship training, events, etc.) aimed at accelerating the development potential of French or European projects, offering innovative products or solutions applied to the field of oncology. The platform is based on a historic partnership with fourteen international laboratories (Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Exact Sciences, GlaxoSmithKline, insitro, MSD, Pfizer, Pierre Fabre, Roche, Sanofi and Takeda) committed to developing partnerships in the field.
Each year MATWIN organizes the European Partnering Convention dedicated to oncology MEET2WIN, which brings together more than 300 European players in the cancer innovation chain and thus promotes collaborations between ecosystems (companies, entrepreneurs, researchers, clinicians, investors, structures support, patient associations, etc.).
